Camille E van Hoorn1,2, Robert B Flint3,4, Justin Skowno5, Paul Davies6, Thomas Engelhardt7,8, Kirk Lalwani9, Olutoyin Olutoye10, Erwin Ista11,12, Jurgen C de Graaff13. 1. Department of Anaesthesiology, Erasmus University Medical Centre -Sophia Children's Hospital, Rotterdam, The Netherlands. c.vanhoorn@erasmusmc.nl. 2. Department of Paediatric Surgery, Erasmus University Medical Centre -Sophia Children's Hospital, PO Box: 2060, 3000 CB, Rotterdam, The Netherlands. c.vanhoorn@erasmusmc.nl. 3. Division of Neonatology, Department of Paediatrics, Erasmus University Medical Centre -Sophia Children's Hospital, Rotterdam, The Netherlands. 4. Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands. 5. Department of Anaesthesiology, Children's Hospital at Westmead, University of Sydney, Sydney, Australia. 6. Department of Anaesthesia and Pain Management, The Royal Children's Hospital, Melbourne, Australia. 7. Department of Anaesthesia, Royal Children's Hospital Aberdeen and School of Medicine, University of Aberdeen, Aberdeen, UK. 8. Department of Anaesthesia, McGill University Health Center, Montreal Children's Hospital, Montreal, QC, Canada. 9. Department of Anaesthesiology and Paediatrics, Oregon Health and Science University, Portland, OR, USA. 10. Department of Anaesthesiology, Peri-operative and Pain Medicine, Texas Children's Hospital, Houston, TX, 77030, USA. 11. Department of Internal Medicine - Nursing Science, Erasmus University Medical Centre, Rotterdam, The Netherlands. 12. Department of Paediatric Surgery, Paediatric Intensive Care, Erasmus University Medical Centre - Sophia Children's Hospital, Rotterdam, The Netherlands. 13. Department of Anaesthesiology, Erasmus University Medical Centre -Sophia Children's Hospital, Rotterdam, The Netherlands.
Abstract
PURPOSE: The purpose of this international study was to investigate prescribing practices of dexmedetomidine by paediatric anaesthesiologists. METHODS: We performed an online survey on the prescription rate of dexmedetomidine, route of administration and dosage, adverse drug reactions, education on the drug and overall experience. Members of specialist paediatric anaesthesia societies of Europe (ESPA), New Zealand and Australia (SPANZA), Great Britain and Ireland (APAGBI) and the USA (SPA) were consulted. Responses were collected in July and August 2019. RESULTS: Data from 791 responders (17% of 5171 invitees) were included in the analyses. Dexmedetomidine was prescribed by 70% of the respondents (ESPA 53%; SPANZA 69%; APAGBI 34% and SPA 96%), mostly for procedural sedation (68%), premedication (46%) and/or ICU sedation (46%). Seventy-three percent had access to local or national protocols, although lack of education was the main reason cited by 26% of the respondents not to prescribe dexmedetomidine. The main difference in dexmedetomidine use concerned the age of patients (SPA primarily < 1 year, others primarily > 1 year). The dosage varied widely ranging from 0.2-5 μg kg-1 for nasal premedication, 0.2-8 μg kg-1 for nasal procedural sedation and 0-4 μg kg-1 intravenously as adjuvant for anaesthesia. Only ESPA members (61%) had noted an adverse drug reaction, namely bradycardia. CONCLUSION: The majority of anaesthesiologists use dexmedetomidine in paediatrics for premedication, procedural sedation, ICU sedation and anaesthesia, despite the off-label use and sparse evidence. The large intercontinental differences in prescribing dexmedetomidine call for consensus and worldwide education on the optimal use in paediatric practice.
PURPOSE: The purpose of this international study was to investigate prescribing practices of dexmedetomidine by paediatric anaesthesiologists. METHODS: We performed an online survey on the prescription rate of dexmedetomidine, route of administration and dosage, adverse drug reactions, education on the drug and overall experience. Members of specialist paediatric anaesthesia societies of Europe (ESPA), New Zealand and Australia (SPANZA), Great Britain and Ireland (APAGBI) and the USA (SPA) were consulted. Responses were collected in July and August 2019. RESULTS: Data from 791 responders (17% of 5171 invitees) were included in the analyses. Dexmedetomidine was prescribed by 70% of the respondents (ESPA 53%; SPANZA 69%; APAGBI 34% and SPA 96%), mostly for procedural sedation (68%), premedication (46%) and/or ICU sedation (46%). Seventy-three percent had access to local or national protocols, although lack of education was the main reason cited by 26% of the respondents not to prescribe dexmedetomidine. The main difference in dexmedetomidine use concerned the age of patients (SPA primarily < 1 year, others primarily > 1 year). The dosage varied widely ranging from 0.2-5 μg kg-1 for nasal premedication, 0.2-8 μg kg-1 for nasal procedural sedation and 0-4 μg kg-1 intravenously as adjuvant for anaesthesia. Only ESPA members (61%) had noted an adverse drug reaction, namely bradycardia. CONCLUSION: The majority of anaesthesiologists use dexmedetomidine in paediatrics for premedication, procedural sedation, ICU sedation and anaesthesia, despite the off-label use and sparse evidence. The large intercontinental differences in prescribing dexmedetomidine call for consensus and worldwide education on the optimal use in paediatric practice.
Entities:
Keywords:
Anaesthesia; Dexmedetomidine; Drug prescriptions; Off-label use; Paediatrics; Pharmacology
Authors: Peter Szmuk; Dean Andropoulos; Francis McGowan; Ansgar Brambrink; Christopher Lee; Katherine J Lee; Mary Ellen McCann; Yang Liu; Rita Saynhalath; Choon Looi Bong; Brian J Anderson; Charles Berde; Jurgen C De Graaff; Nicola Disma; Dean Kurth; Andreas Loepke; Beverley Orser; Daniel I Sessler; Justin J Skowno; Britta S von Ungern-Sternberg; Laszlo Vutskits; Andrew Davidson Journal: Paediatr Anaesth Date: 2019-01 Impact factor: 2.556
Authors: Carmen Sulton; Courtney McCracken; Harold K Simon; Kiran Hebbar; Jason Reynolds; Joseph Cravero; Michael Mallory; Pradip Kamat Journal: Hosp Pediatr Date: 2016-08-11
Authors: Mihaela A Damian; Gregory B Hammer; Mohammed H Elkomy; Adam Frymoyer; David R Drover; Felice Su Journal: Anesth Analg Date: 2020-01 Impact factor: 5.108
Authors: Mary Weatherall; Riku Aantaa; Giorgio Conti; Chris Garratt; Pasi Pohjanjousi; Michael A Lewis; Nicholas Moore; Susana Perez-Gutthann Journal: Br J Clin Pharmacol Date: 2017-05-10 Impact factor: 4.335
Authors: Camille E van Hoorn; Sanne E Hoeks; Heleen Essink; Dick Tibboel; Jurgen C de Graaff Journal: Paediatr Anaesth Date: 2019-01-15 Impact factor: 2.556
Authors: Jolien J M Freriksen; Tjitske M van der Zanden; Inge G A Holsappel; Bouwe Molenbuur; Saskia N de Wildt Journal: Paediatr Drugs Date: 2022-03-28 Impact factor: 3.930
Authors: Kristina Liaudanskytė; Ilona Razlevičė; Tomas Bukauskas; Vilija Stremaitytė; Laura Lukošienė; Andrius Macas Journal: Med Sci Monit Date: 2022-07-24